A luminescent compound has a structure represented by a general formula (1),

##STR00001##

wherein R represents a luminescent dye skeleton, X represents an ionic substituent, and L represents a single bond, an oxygen atom, a sulfur atom, a selenium atom, or an NH group.

A luminescent compound has a structure represented by a general formula (1),

##STR00001##

wherein R represents a luminescent dye skeleton, X represents an ionic substituent, and L represents a single bond, an oxygen atom, a sulfur atom, a selenium atom, or an NH group.

Disclosed herein are kinase inhibitor compounds having the structure (I) or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R.sup.1, R.sup.2, X, L, Q, and Y are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

##STR00001##

The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

The present disclosure relates to a boron compound applicable to an organic light-emitting diode and an organic light-emitting diode comprising same. More specifically, the present disclosure relates to a boron compound represented by any one of Chemical Formulas A to D and an organic light-emitting diode comprising same, wherein Chemical Formulas A to D are as defined in the description.

Provided is an organic light emitting device including a light emitting layer comprising a compound of Chemical Formula 1 and a first organic material layer comprising a compound of Chemical Formula 2:

##STR00001## wherein: Cy1 to Cy5 are each independently one selected from among a substituted or unsubstituted: aromatic hydrocarbon ring, aliphatic hydrocarbon ring, and aromatic hetero ring, or a ring in which two or more rings selected from the above group are fused, one or more of Cy1 to Cy5 are a ring of Chemical Formula 1-A:

##STR00002## one to three of a* to d* are a position fused to or linked to Chemical Formula 1;

##STR00003## L1 to L3 are each independently a direct bond or a substituted or unsubstituted: arylene or divalent heterocyclic group; and Ar1 and Ar2 are each independently a substituted or unsubstituted: aryl or heterocyclic group.

An intermediate is provided herein, and it has the structure shown in the formula (1) as follows:

##STR00001##

formula (1). In the formula (1), R.sub.1 is —Cl, —Br, —I, —OSO.sub.2CF.sub.3, —B(OH).sub.2, or

##STR00002##

R.sub.2 is —F, —.sup.18F, —Cl, —Br, —I, —SnMe.sub.3, —SnBu.sub.3, —B(OH).sub.2, or

##STR00003##

and A is a chiral auxiliary.

An intermediate is provided herein, and it has the structure shown in the formula (1) as follows:

##STR00001##

formula (1). In the formula (1), R.sub.1 is —Cl, —Br, —I, —OSO.sub.2CF.sub.3, —B(OH).sub.2, or

##STR00002##

R.sub.2 is —F, —.sup.18F, —Cl, —Br, —I, —SnMe.sub.3, —SnBu.sub.3, —B(OH).sub.2, or

##STR00003##

and A is a chiral auxiliary.

The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt:

##STR00001##

wherein X.sub.1, X.sub.2, X.sub.3 and X.sub.4 are each independently —CR.sub.2═ or —N═, R.sub.2 is, for example, a halogen atom, R.sub.1 is, for example, —S(═O).sub.2—NH—R.sub.8, R.sub.8 is, for example, a C1-6 alkyl group, R.sub.3 is, for example, a hydrogen atom, R.sub.5 is, for example, a halogen atom, R.sub.6 is, for example, a hydrogen atom, and R.sub.4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

A compound of formula (1)

##STR00001##

wherein X.sub.1 is CR.sub.1 or a nitrogen atom, X.sub.2 is CR.sub.2 or a nitrogen atom, X.sub.3 is CR.sub.3 or a nitrogen atom, X.sub.4 is CR.sub.4 or a nitrogen atom, X.sub.5 is CR.sub.5 or a nitrogen atom, X.sub.6 is CR.sub.6 or a nitrogen atom, X.sub.7 is CR.sub.7, a nitrogen atom, or a carbon atom single-bonded to X.sub.8, X.sub.8 is CR.sub.8, a nitrogen atom, or a carbon atom single-bonded to X.sub.7, X.sub.9 is CR.sub.9 or a nitrogen atom, X.sub.10 is CR.sub.10 or a nitrogen atom, X.sub.11 is CR.sub.11 or a nitrogen atom, X.sub.12 is CR.sub.12 or a nitrogen atom, and Q is CR.sub.Q or a nitrogen atom, and Y is NR.sub.Y1, an oxygen atom, a sulfur atom, C(R.sub.Y2)(R.sub.Y3) or Si(R.sub.Y4)(R.sub.Y5), each R being a hydrogen atom or a substituent.